Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemetostat Combined With Anlotinib in Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma
NCT07917949Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in soft tissue sarcoma (STS), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Progression Free Survival at 12 months. Started Nov 2026; status: recruiting.
02
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07917949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917949.